What Bonothyrk is
Bonothyrk is the parathyroid entry in the Cytomax range: the extracted, rather than synthesised, half of Vladimir Khavinson's bioregulator programme. It is an oral capsule, carrying the designation A-21, sold in short courses around calcium balance and bone.
What is in the capsule is not a defined molecule. It is a crude, water-soluble fraction of low-molecular-weight peptides, which the manufacturer specifies as up to roughly 5,000 daltons, pulled from the parathyroid glands of young cattle or pigs.
That matters to you before anything else. A single synthetic peptide can be verified by its sequence and mass. A gland extract cannot, so from the first line you are dealing with a mixture nobody has fully characterised.
Bonothyrk is not teriparatide
The word "parathyroid" attaches Bonothyrk to a heavily trialled osteoporosis drug it has no relationship with, and vendor copy rarely works to keep the two apart.
That drug is teriparatide, a recombinant fragment of human parathyroid hormone, injected daily, approved for osteoporosis on the back of a randomised trial in 1,637 postmenopausal women.1 Bonothyrk is an oral animal-gland extract with none of that evidence behind it.
They share a gland, not a data set. When a sales page drifts from "parathyroid peptide" into bone-density language, it is borrowing teriparatide's clinical history for a capsule that never earned it.
Capsule and sublingual: the only two formats
Bonothyrk is sold as capsules, typically stated at 10 mg of active substance, sometimes as a sublingual version. There is no injectable Bonothyrk, which sets it apart from the compounds the actual research protocols used.
The question is narrow: what has been measured for this specific capsule, and in whom. Almost nothing, and almost nobody.
02 / MechanismHow Bonothyrk is proposed to work
The mechanism for Bonothyrk is a hypothesis applied to an organ, not a finding measured in one. What follows is what the Cytomax programme proposes about parathyroid tissue, not what anyone has recorded happening in it.
The Khavinson bioregulator hypothesis
The governing idea across the Cytomax range is that short peptides drawn from a given organ carry signalling information relevant to that same organ, and can nudge its ageing tissue back toward normal function.2
In cell culture, Khavinson's group reported that tissue-specific peptide preparations stimulated the outgrowth of explants from their matching organ but not from others.2 A related study found an effective concentration of 0.05 ng/ml stimulated matching tissues in young and old rats.3
That is the strongest mechanistic thread the range has, and it is where the parathyroid story goes quiet. Those tissue-culture experiments were run on heart, lung, prostate and pancreas, not parathyroid.3
What the parathyroid glands actually do
The parathyroid glands are four rice-grain-sized glands in your neck that govern calcium. They release parathyroid hormone, which pulls calcium from bone, conserves it in the kidney, and raises blood calcium when it falls too low.
Calcium sits in a tightly controlled loop between bone, kidney and blood. That is not a system you want a poorly characterised extract nudging without a clinician watching.
The hypothesis is coherent and, for some organs, backed by cell data. The leap the marketing makes is from "organ peptides act on their organ in a dish" to "this parathyroid capsule regulates your calcium and protects your bones." No study has taken that step for Bonothyrk.
What the evidence on Bonothyrk actually shows
PubMed carries no indexed study of Bonothyrk, and none of any parathyroid peptide bioregulator, in any language.
Everything below is borrowed: platform-level cell work on other organs, animal data on other peptides, and one report the developer never published. None of it was measured on a parathyroid extract.
Cell and in-vitro studies on parathyroid peptides
The Cytomax hypothesis rests on organotypic culture work showing organ peptides stimulate their own tissue.2,3 This is real cell data for the platform, and it is the honest basis of the whole range.
None. The published tissue-culture experiments tested heart, lung, prostate and pancreas explants, not parathyroid.3 The parathyroid mechanism is assumed by analogy, not demonstrated.
Take the platform data at face value and it still tells you nothing about this capsule. Not one cell study has put a parathyroid extract onto parathyroid tissue and measured what happened.
Animal studies on parathyroid and bone peptides
Khavinson's experimental review summarises animal studies where peptide bioregulators raised lifespan and inhibited carcinogenesis.4 That work covers the thymic and pineal peptides, not the parathyroid extract.
The nearest published bone signal is for Sigumir, a cartilage-and-bone polypeptide complex, and the AED tripeptide in osteoarthritis models.5 That is a different preparation aimed at joints, not Bonothyrk and not calcium regulation.
No published animal study of Bonothyrk or a parathyroid bioregulator on calcium, bone density or gland function. The animal case for this specific compound is empty.
Human studies on Bonothyrk (read the small print)
There is one human report attached to Bonothyrk, and you should know exactly what it is. It is a single, unblinded, non-randomised study run by the developer, and it was never peer-reviewed or indexed in PubMed.
It has no placebo arm, no independent replication and no route to the primary data, and no PMID exists to cite it by. A sceptic has nothing here to check.
Khavinson's own clinical-studies review of the range names Timalin, Thymogen, Vilon, Epithalamin, Prostatilen, Cortexin and Retinalamin as the peptides with clinical results.6 Bonothyrk is not on the list.
When the group that developed the peptide writes up its own clinical evidence and leaves this product out, the capsule sits outside even the developer's own record. We read that omission as harder evidence than anything a vendor prints.
What remains unproven
No cell study, no animal study, and no peer-reviewed human trial has tested whether swallowing this parathyroid extract does anything to your calcium, your bones or your parathyroid glands.
That does not make the underlying platform fraudulent. It makes Bonothyrk a compound with a plausible-sounding hypothesis, a real extraction method, and effectively no evidence of its own. We put it close to the bottom of the range.
04 / Benefits by evidenceBonothyrk benefits: the claims, and what the evidence supports
The word parathyroid is doing the selling on all three of these claims. Strip it out, ask what has been measured on the capsule, and they separate immediately.
Weakly plausible. The tissue-specific hypothesis has cell backing for other organs,2,3 so it is not baseless. It is also unmeasured for parathyroid, so any benefit here is inference, not a demonstrated outcome in you.
Unsupported for this product. The real bone-density evidence belongs to teriparatide, a different drug entirely.1 Buying Bonothyrk for your bones is buying teriparatide's reputation without teriparatide.
Least supported. The range's lifespan data is for other peptides,4 and Bonothyrk is absent from the developer's own clinical review.6 Treat a longevity claim on this capsule as marketing, not a finding.
The hierarchy runs opposite to the pitch. The boldest promises, bone protection and slower ageing, carry no evidence for this compound, while the modest idea of generic organ signalling rests on cell data from other tissues. We would not buy this one for bone.
05 / Dosage and protocolBonothyrk dosage and protocol
Nothing here is a recommendation to dose yourself. There is no dose-finding trial for Bonothyrk, so every figure below is Cytomax convention carried over from the other capsules in the range.
How to take Bonothyrk: the protocol as sold
Bonothyrk is commonly sold at 10 mg per capsule, taken as one or two capsules once or twice daily for a course of 10 to 30 days, then repeated once or twice a year.
Those numbers come from vendor labels and the wider Cytomax convention, not from a study of this compound. Any page presenting them as a clinically established dose is quoting a label, not a trial.
Why the oral route is doubly unresolved
A peptide fraction faces digestion in the gut, and how much of a mixture up to roughly 5,000 daltons survives to act systemically is unestablished. For a defined peptide that question is at least askable; for a crude extract it is barely definable.
You are dosing an uncharacterised mixture, by a route nobody has shown delivers it, on a schedule nobody validated.
06 / Safety and side effectsBonothyrk safety and side effects
Vendors describe Bonothyrk as well tolerated, with no serious adverse events reported. Nobody has run a study designed to find any, and this capsule aims at a system where a shift would not announce itself to you.
Why "no side effects reported" is misleading
Nobody ran a safety trial. The single developer report was small, short, and looking for benefit rather than harm, and a study that never asks about side effects will not find any. Silence in that record is not a clean record.
The parathyroid-specific risk
This is where Bonothyrk differs from most bioregulators. The parathyroid system controls blood calcium, and disturbing it in either direction has real consequences: too much parathyroid activity strips calcium from bone and raises it in blood.
Teriparatide, the licensed parathyroid drug, is deliberately dosed and monitored precisely because it acts on this axis; its own trial reported only minor effects at controlled doses.1 Bonothyrk offers you the parathyroid target with none of that oversight.
No study has shown Bonothyrk shifts your calcium at all, so this is a caution about an uncharacterised product aimed at a sensitive system, not a documented event.
Who should not take Bonothyrk, and the product risk
Avoid Bonothyrk if you are pregnant or breastfeeding, if you have any disorder of calcium, bone or the parathyroid glands, or if you take calcium or vitamin D at doses your doctor has not set. Kidney disease or a history of kidney stones is another reason to steer clear.
What is most likely to harm you is the manufacturing rather than the parathyroid fraction. A crude animal-tissue extract carries risks of contamination and mislabelling, and you have no sequence to verify what is inside.
If you are considering an unlicensed extract aimed at your calcium, the person to ask is a GP or endocrinologist who can order a blood test and read your history. No vendor page substitutes for that number.
07 / SourcingWhere to buy Bonothyrk safely in the UK
Bonothyrk is harder to verify than a synthetic peptide, because there is nothing to verify against. No UK pharmacy stocks it, so every route in is an import or a reseller, and neither comes with a regulator behind it.
With Epitalon you can demand a sequence and a mass. With a gland extract you cannot, so trust does more work than testing.
What actually arrives in the blister pack
What lands is often a blister pack with a Cyrillic label, no certificate of analysis, and no way to confirm the capsules hold cattle or pig parathyroid extract rather than filler. No independent lab has checked the batch in your hand, and for a crude mixture there is no clean test that could.
How to reduce the risk when buying Bonothyrk
Prefer suppliers who name the manufacturer and the source tissue, publish whatever testing exists, and do not lean on teriparatide's bone research to sell you an extract. Treat a price far below the market as a warning to you, not a bargain.
A verified-genuine Bonothyrk capsule is still a compound with no trial of its own, so careful buying gets you an authentic version of something the evidence has not backed. Our where to buy guide sets out what to ask a supplier for.
08 / ComparisonBonothyrk vs teriparatide, Sigumir and the wider range
Teriparatide is a defined recombinant peptide, injected, dose-controlled, and proven in a randomised trial to cut fractures and raise bone density.1 Bonothyrk shares its target gland and nothing else.
Set against its own family, Bonothyrk sits behind the peptides that carry the range's real evidence. Epithalamin, Cortexin, Prostatilen and the others at least appear in the developer's clinical review.6 Bonothyrk does not.
Set against Sigumir, the same problem repeats. Sigumir has a plausible source tissue and no trial of its own, and its nearest published signal is a cartilage and osteoarthritis model, not calcium regulation.5
If bone is why you are here, Sigumir is the closer match on paper. That tells you how thin the parathyroid case is, not that Sigumir works.
If you are weighing the bioregulators against each other, the parathyroid entry is one of the thinnest in the set, and its target is one of the most consequential to get wrong. We map the full range, and where each compound's evidence really stands, on our types of bioregulators guide.
Frequently Asked Questions
What is Bonothyrk made from?
It is made from the parathyroid glands of young cattle or pigs. What is extracted is a water-soluble fraction of low-molecular-weight peptides, which the manufacturer specifies as up to roughly 5,000 daltons, rather than a defined molecule. Because it is an extract, there is no sequence or mass to check it against.
What is peptide bioregulator A-21?
A-21 is simply the catalogue designation for Bonothyrk in the Khavinson Cytomax range. It is a naming convention, nothing more, and it carries no evidence with it. Vendor pages lean on it because a code makes a crude gland extract sound like a characterised compound.
Is there any clinical evidence for Bonothyrk?
None that has been peer-reviewed. PubMed has no indexed trial of Bonothyrk, and the only human report is a single unblinded, non-randomised study run by the developer that was never peer-reviewed. There is no controlled evidence a sceptic would accept.
Is Bonothyrk the same as parathyroid hormone or teriparatide?
No. Teriparatide is a defined, injected, licensed drug proven to cut fractures in a randomised trial. Bonothyrk is an oral crude extract of animal parathyroid glands with no such evidence. They share a gland, not a data set.
Does Bonothyrk help with osteoporosis or bone density?
Nothing shows that it does. The bone-density evidence belongs to teriparatide, a different compound. No study has tested whether swallowing this parathyroid extract affects your calcium or bones at all, so the bone claim is borrowed, not demonstrated.
What is the recommended Bonothyrk dosage?
There is no validated dose. Vendors commonly suggest 10 mg capsules, one or two, once or twice daily for 10 to 30 days, repeated once or twice a year. Those figures are Cytomax convention, not a clinically established dose.
Is Bonothyrk safe to take?
Its safety is unknown, not established. No safety trial exists, and it acts on the calcium-regulating parathyroid system, which is not one to disturb blindly. If you have any calcium, bone, kidney or parathyroid condition, this is a conversation for your doctor first.
Why is Bonothyrk missing from Khavinson's clinical review?
His clinical-studies review lists the peptides with clinical results: Timalin, Thymogen, Vilon, Epithalamin, Prostatilen, Cortexin and Retinalamin. Bonothyrk is absent. The most likely reading is that it has no clinical dataset worth reviewing.
Is Bonothyrk legal to buy in the UK?
It is not approved by the MHRA, the FDA or the EMA, and reaches UK buyers as an imported supplement rather than a registered medicine. Nothing about that import route is checked by a regulator, and the risk sits with you.
- Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001;344(19):1434–1441. PMID: 11346808.
- Khavinson VKh. Peptides and Ageing. Neuro Endocrinol Lett. 2002;23 Suppl 3:11–144. PMID: 12374906.
- Zakutskii AN, Chalisova NI, Ryzhak GA, et al. [The tissue-specific effect of synthetic peptides-biologic regulators in organotypic tissues culture in young and old rats]. Adv Gerontol. 2006;19:93–96. PMID: 17152728.
- Khavinson VKh, Kuznik BI, Ryzhak GA. [Peptide bioregulators: the new class of geroprotectors. Communication 1. Results of experimental studies]. Adv Gerontol. 2012;25(4):696–708. PMID: 23734519.
- Myakisheva SN, Linkova NS, Kozhevnikova EO, Ryzhak GA. [Chondrocytes secretory phenotype associated with aging: role in the pathogenesis of osteoarthritis and prospects for peptide bioregulation]. Adv Gerontol. 2023;36(3):313–323. PMID: 37782637.
- Khavinson VKh, Kuznik BI, Ryzhak GA. [Peptide bioregulators: the new class of geroprotectors. Message 2. Clinical studies results]. Adv Gerontol. 2013;26(1):20–37. PMID: 24003726.